Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and a relative lack of insulin \[[@CR1]\]. It is also a risk factor for other serious conditions, such as neuropathy, nephropathy, arteriosclerosis, and vascular events, including ischemic heart disease, stroke, and peripheral artery disease \[[@CR1]\]. The number of diabetic patients worldwide is increasing, which poses a serious challenge to public health \[[@CR2], [@CR3]\]. If the current trend continues, it is estimated that this number will surpass 700 million patients by 2025 \[[@CR4]\]. It is therefore critical to treat the disease early and with the appropriate treatment regimen. Management of T2DM includes diet and regular exercise; however, some people are unable to achieve target plasma glucose levels with this approach alone. Therefore, diabetes medication and insulin therapy may be needed \[[@CR1]\].

Currently, there are several oral antidiabetic drugs available, including biguanides (e.g., metformin) and thiazolidinediones to improve insulin sensitivity \[[@CR5]\]; sulfonylureas to aid insulin secretion \[[@CR5]\]; dipeptidyl peptidase-4 inhibitors to reduce plasma glucose levels \[[@CR5]\]; α-glucosidase inhibitors to suppress or delay intestinal absorption \[[@CR5]\]; and most recently, sodium--glucose co-transporter 2 inhibitors to enhance glucose excretion in urine \[[@CR5]\]. Diabetic patients who have poor glycemic control through monotherapy can be treated with a combination of these agents that differ in their mechanisms of action \[[@CR5]\].

As pancreatic β-cell dysfunction is a major contributor to T2DM progression, drugs with a mechanism of action that helps insulin secretion in pancreatic β-cells may offer a new therapeutic approach for T2DM. The G protein-coupled receptor 119 (GPR119), which has been shown to be highly expressed in the human gastrointestinal tract (small intestinal L-cells) and pancreas (β-cells), has been identified as a novel target for antidiabetic drugs \[[@CR6], [@CR7]\]. On the basis of the results of several in vitro studies, it is expected that GPR119 agonists will reduce blood glucose levels by promoting insulin secretion in a glucose-dependent manner and improve pancreatic β-cell function over long-term treatment \[[@CR7]--[@CR9]\].

DS-8500a is a novel GPR119 agonist developed by Daiichi Sankyo Co., Ltd. In non-clinical pharmacology studies, DS-8500a exerted agonistic activity in Chinese hamster ovary-K1 cells expressing human GPR119 and reversed glucose tolerance in Zucker fatty rats in an animal model of glucose intolerance \[[@CR10]\]. A phase 1 study of DS-8500a performed in healthy Japanese men reported that a single oral dose of DS-8500a capsules up to 600 mg and 7-day multiple oral doses of up to 300 mg/day were tolerated by the subjects \[[@CR11]\]. In another phase 1 study, 7-day multiple oral doses of DS-8500a tablets up to 100 mg/day were tolerated by healthy subjects \[[@CR11]\]. Results from a phase 2a study in T2DM patients evaluating DS-8500a administered at 10 or 75 mg for 4 weeks showed a significant decrease in 24-h weighted mean glucose levels in both the DS-8500a 10-mg and 75-mg groups compared with the placebo group (− 13.3 and − 18.9 mg/dL, respectively). DS-8500a was well tolerated at both doses with no reports of serious adverse events (SAEs), clinically significant AEs, or AEs that led to treatment discontinuation \[[@CR12]\].

On the basis of the above findings, we conducted a phase 2b, double-blind, parallel-group study in Japanese T2DM patients. The aim of this study was to evaluate the efficacy, safety, and dose of DS-8500a compared with placebo in patients with T2DM after a 12-week oral administration of DS-8500a at 25, 50, or 75 mg. We also investigated the efficacy of DS-8500a, relative to the active comparator sitagliptin 50 mg.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a phase 2b, randomized, placebo-controlled, active-controlled, double-blind, 5-parallel-group study conducted in T2DM patients to evaluate efficacy and safety of DS-8500a 25, 50, and 75 mg administered orally for 12 weeks (Fig. [1](#Fig1){ref-type="fig"}). This study was conducted at 25 sites in Japan (Supplementary Table S1). Subjects who received antidiabetic drugs within 90 days prior to initiation underwent a 28-day washout period (observation period 1). This was followed by observation period 2 comprising a 2-week washout period for all subjects (those who did and did not receive any antidiabetic drugs within 90 days prior to initiation). Subjects were registered during observation period 3 prior to randomization. A randomization schedule was prepared by an independent biostatistician using hemoglobin A1c (HbA1c) at observation period 2 (≤ 8.0% or \> 8.0%) as a stratification factor (permuted block method). Subjects were randomized in a ratio of 1:1:1:1:1 to the DS-8500a 25/50/75-mg, sitagliptin 50-mg, or placebo groups according to the schedule. Blinding was maintained by the independent biostatistician and those involved in the assignment, packaging, and quality assurance of study drugs.Fig. 1Study design. ^\*1^Subjects who received a single antidiabetic drug within 90 days prior to the initiation of the observation period: 6 weeks. ^\*2^Subjects who had not received an antidiabetic drug within 90 days prior to the initiation of the observation period: 2 weeks

This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Pharmaceutical Affairs Law, Good Clinical Practice, and associated Japanese regulations. The study protocol was approved by the institutional review board at each site and all patients provided written informed consent.

Patients {#Sec4}
--------

Eligible subjects for this study were Japanese patients with T2DM and ≥ 20 years of age at the time of informed consent, with HbA1c ≥ 7.0% and \< 10.0% during observation period 2. Patients were eligible regardless of whether they had received antidiabetic drugs within 90 days prior to enrolment. The exclusion criteria included type 1 DM or a history of diabetic coma, precoma, or ketoacidosis; clinically significant diabetic retinopathy, nephropathy, or neuropathy; insulin therapy; thiazolidinedione therapy within 90 days before the initiation of the observation period; poorly controlled blood pressure \[sustained systolic (≥ 160 mmHg) or diastolic (≥ 100 mmHg) hypertension\]; and body mass index (BMI) of \< 18.5 or ≥ 35.0 kg/m^2^.

Treatment {#Sec5}
---------

During observation period 3, each subject was administered three placebo tablets and one placebo capsule to be taken orally once daily after breakfast for 14 days. During the treatment period, the study drugs (DS-8500a 25, 50, or 75 mg; sitagliptin 50 mg; or placebo) were administered orally after breakfast for 12 weeks. Concomitant drugs and therapies prohibited during the study included antidiabetic drugs, anorexiants, drugs that could affect the pharmacodynamics evaluation, drugs that might cause drug--drug integrations, and other study drugs. The complete list of restricted and prohibited concomitant drugs is found in the Supplementary Information (Table S2).

Efficacy and Safety Endpoints and Evaluation Criteria {#Sec6}
-----------------------------------------------------

The primary efficacy endpoint was the change from baseline (day − 1) in HbA1c at week 12. The secondary efficacy endpoints included the change from baseline in HbA1c at weeks 4 and 8, the proportion of subjects who achieved HbA1c \< 7.0% at week 12, the change from baseline to week 12 in fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hr-PPG), and pharmacodynamic parameters derived from plasma glucose. Other secondary efficacy endpoints were changes from baseline at each post-dose time point in serum insulin, proinsulin, C-peptide, and 1,5-anhydroglucitol; pharmacodynamic parameters derived from serum insulin, C-peptide, peptide YY (PYY), total glucagon-like peptide-1 (GLP-1), active GLP-1, total glucose-dependent insulinotropic polypeptide (GIP), and glucagon; and total cholesterol, high-density lipoprotein (HDL-) and low-density lipoprotein (LDL-) cholesterol, and triglycerides (TGs).

AEs and safety outcomes including laboratory values, electrocardiography, body weight, and vital signs were recorded throughout the study. All hypoglycemia events were defined as clinically relevant drug-related hypoglycemia in accordance with the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents (Notification No. 0709-1 \[9 Jul 2010\] by the Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labour and Welfare). Asymptomatic hypoglycemia was defined as a blood glucose level of ≤ 70 mg/dL without any typical hypoglycemic symptoms. Such asymptomatic events correspond to level 1 hypoglycemia according to the definition provided by the American Diabetes Association (ADA) and the International Hypoglycaemia Study Group \[[@CR13]\].

Statistical Methods {#Sec7}
-------------------

The sample size was determined on the basis of a pairwise comparison between DS-8500a at each dose group vs placebo, based on "On Release of the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents" \[[@CR14]\] and the primary endpoint, change from baseline in HbA1c at week 12. As there are no available data on change in HbA1c at week 12 after administration of DS-8500a, the sample size was selected in reference to the results of a previous study investigating the change in 24-h weighted mean glucose level at week 4 \[[@CR12]\], and the results of a clinical study \[[@CR15]\] investigating HbA1c after administration of sitagliptin. It was assumed that the changes in HbA1c at week 12 in the placebo, DS-8500a 25-mg, 50-mg, and 75-mg groups were 0.0%, − 0.6%, − 0.9%, − 1.0%, respectively, and that the standard deviation in each treatment group was 1.0%. Accordingly, a sample size of 60 patients per group was required to detect the superiority of DS-8500a at a statistical power of 90% at a two-sided significance level of 5% in a pairwise comparison between the placebo group and each DS-8500a group. To account for a dropout rate of approximately 10%, a sample size of 67 patients per group (335 patients in total) was planned. The efficacy analysis was performed in the full analysis set (FAS), and the sensitivity analysis was performed in the per protocol set (PPS).

The primary endpoint was analyzed using an analysis of covariance (ANCOVA) model, with the treatment group as a fixed effect and HbA1c at baseline and presence/absence of diabetes drug use within 90 days before informed consent as covariates, and compared between each DS-8500a group and the placebo group. A fixed-sequence testing approach from high dose to low dose was used to adjust for multiplicity of comparisons. A comparison between each DS-8500a group and the sitagliptin group was performed in a similar manner using an ANCOVA model, using the treatment group as a fixed effect and HbA1c at baseline as a covariate. For each comparison, the 95% confidence intervals and *p* values were calculated with a significance level of 5% (two-sided). The secondary endpoints were summarized for each treatment group at each time point. The safety analysis was performed in the safety analysis set, and the safety endpoints were summarized for each treatment group at each time point.

Missing data for the primary endpoint (change in HbA1c at week 12) were imputed with data obtained after the initiation of study treatment in accordance with the last observation carried forward (LOCF) method. Data for week 12 imputed by LOCF were presented as "week 12 (LOCF)" to be distinguished from data for week 12 that were not imputed.

The statistical analyses were performed using SAS system release 9.2 (SAS Inc., Cary, NC, USA).

Results {#Sec8}
=======

Patients {#Sec9}
--------

The disposition of patients is summarized in Fig. [2](#Fig2){ref-type="fig"}. There were 453 patients assessed for eligibility, 368 of whom were randomized. Eighty-five patients were excluded prior to randomization for the following reasons: did not meet inclusion criteria (*n* = 50); met exclusion criteria (*n* = 35).Fig. 2Patient disposition. "Analyzed" refers to the full analysis set rather than the per protocol set

The placebo arm enrolled 73 patients; 73, 74, and 73 patients were enrolled in the DS-8500a 25-mg, 50-mg, 75-mg groups, respectively; and 75 patients were enrolled in the sitagliptin 50-mg group. The number of patients analyzed in each group was 72 for the placebo and DS-8500a groups, and 75 for sitagliptin. The losses from each group due to withdrawal of consent, AEs, or other are shown in Fig. [2](#Fig2){ref-type="fig"}.

The baseline characteristics of the patients were similar, with no significant differences with respect to age, sex, BMI, disease duration, or prior medication use (Table [1](#Tab1){ref-type="table"}).Table 1Baseline patient characteristicsPlaceboDS-8500a 25 mgDS-8500a 50 mgDS-8500a 75 mgSitagliptin 50 mgTotal*n* = 72*n* = 72*n* = 72*n* = 72*n* = 75*N* = 363Age (years)61.5 ± 8.559.5 ± 9.361.4 ± 9.561.3 ± 8.561.1 ± 9.461.0 ± 9.0Sex Male57 (79.2)53 (73.6)51 (70.8)57 (79.2)61 (81.3)279 (76.9) Female15 (20.8)19 (26.4)21 (29.2)15 (20.8)14 (18.7)84 (23.1)BMI (kg/m^2^)25.21 ± 3.6924.59 ± 3.3925.19 ± 3.7325.59 ± 3.3424.81 ± 3.2925.08 ± 3.49Duration of DM (years)8.26 ± 6.086.75 ± 4.848.36 ± 6.097.57 ± 6.337.97 ± 5.457.79 ± 5.78Prior use of OHAs Absence30 (41.7)32 (44.4)27 (37.5)33 (45.8)30 (40.0)152 (41.9) Presence42 (58.3)40 (55.6)45 (62.5)39 (54.2)45 (60.0)211 (58.1)HbA1c (%)7.96 ± 0.697.93 ± 0.718.07 ± 0.887.99 ± 0.758.04 ± 0.768.00 ± 0.76FPG (mg/dL)193.1 ± 29.1193.1 ± 29.1203.6 ± 40.9199.6 ± 34.6199.9 ± 33.5199.3 ± 34.2Results are presented as the mean ± standard deviation or n (%)*BMI* body mass index, *DM* diabetes mellitus, *OHAs* oral hypoglycemic agents, *HbA1c* hemoglobin A1c, *FPG* fasting plasma glucose

Efficacy {#Sec10}
--------

Compared with placebo, treatment with DS-8500a at 25 mg, 50 mg, and 75 mg showed a statistically significant dose-dependent decrease in HbA1c levels from baseline at weeks 4, 8, and 12 (Fig. [3](#Fig3){ref-type="fig"}). At week 12, the change in HbA1c from baseline compared with placebo was − 0.23% (*p* = 0.0173), − 0.37% (*p* = 0.0001), and − 0.44% (*p* \< 0.0001) in the DS-8500a 25-mg, 50-mg, and 75-mg groups, respectively (Fig. [3](#Fig3){ref-type="fig"}). However, compared with sitagliptin, DS-8500a did not show greater lowering effects on HbA1c (Fig. [3](#Fig3){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}).Fig. 3Change in HbA1c from baseline to week 12. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs placebo Table 2Pharmacodynamic resultsPlacebo (*n* = 72)25 mg DS-8500a (*n* = 72)50 mg DS-8500a (*n* = 72)BaselineWeek 12Change from baseline to week 12BaselineWeek 12Change from baseline to week 12LSM difference vs placeboBaselineWeek 12Change from baseline to week 12LSM difference vs placeboHbA1c (%)7.968.180.177.937.94− 0.02− 0.23^†^8.077.95− 0.15\*− 0.37^†††^Fasting plasma glucose(mg/dL)172.5164.2− 6.6\*\*169.6157.3− 12.6\*\*\*− 5.9175.7152.8− 19.3\*\*\*− 12.72-hour postprandial glucose (mg/dL)266.3259.8− 0.8248.9238.6− 12.4\*− 11.6259.5235.7− 19.3\*\*\*− 18.5†Fasting insulin (µU/mL)9.209.09− 0.138.828.940.010.149.929.59− 0.130.00Fasting C-peptide (ng/mL)1.691.55− 0.131.621.44− 0.21\*\*\*− 0.081.761.52− 0.22\*\*\*− 0.081,5-Anhydroglucitol (µg/mL)4.694.75− 0.034.814.970.080.114.685.050.220.25Proinsulin (pmol/L)9.309.290.178.188.780.410.249.297.98− 1.13\*\*− 1.31^††^Glucose AUC~0--3h~ (mg/dL × h)758.4737.9− 6.4720.5685.5− 38.4\*\*\*− 32.0^†^747.6676.8− 57.0\*\*\*− 50.6^††^Insulin AUC~0--3h~ (µU/mL × h)119.6127.25.8113.2128.013.1\*\*7.3128.4145.015.2\*\*\*9.3C-peptide AUC~0--3h~ (ng/mL × h)12.5211.66− 0.91\*\*\*11.9311.31− 0.80\*\*\*0.1012.9312.34− 0.68\*\*0.23PYY AUC~0--3h~ (pg/mL × h)515.5421.0− 91.4\*\*\*488.5454.0− 49.9\*\*\*41.5^††^511.1458.5− 50.4\*\*\*41.0^††^Active GLP-1 AUC~0--3h~ (pmol/L × h)14.215.61.214.215.91.40.215.015.40.5− 0.8Total GLP-1 AUC~0--3h~ (pmol/L × h)29.535.86.60\*\*\*28.236.38.51\*\*\*1.9129.235.76.65\*\*\*0.05Glucagon AUC~0--3h~ (pg/mL × h)421.6442.426.6\*\*398.6452.249.7\*\*\*23.1419.4445.030.0\*\*3.5GIP AUC~0--3h~ (pg/mL × h)1355.01260.4− 65.51209.71416.2192.6\*\*\*258.1^†††^1163.81478.6298.3\*\*\*363.7^†††^75 mg DS-8500a (*n* = 72)50 mg sitagliptin (*n* = 75)BaselineWeek 12Change from baseline to week 12LSM difference vs placeboBaselineWeek 12Change from baseline to week 12LSM difference vs placeboHbA1c (%)7.997.74− 0.27\*\*\*− 0.44^†††^8.047.29− 0.78\*\*\*− 0.97^†††^Fasting plasma glucose(mg/dL)170.8^†††^149.4− 21.0\*\*\*− 14.4^†††^174.4143.0− 29.2\*\*\*− 22.6^†††^2-hour postprandial glucose (mg/dL)260.2234.8− 22.8\*\*\*− 22.0^††^264.6197.3− 61.9\*\*\*− 61.1^†††^Fasting insulin (µU/mL)9.779.18− 0.31− 0.188.728.830.070.20Fasting C-peptide (ng/mL)1.731.49− 0.22\*\*\*− 0.091.661.51− 0.16\*\*\*− 0.31,5-Anhydroglucitol (µg/mL)4.644.760.020.054.989.854.70\*\*\*4.74^†††^Proinsulin (pmol/L)9.187.77− 1.06\*\*− 1.24†8.616.46− 2.04\*\*\*− 2.22^†††^Glucose AUC~0--3h~ (mg/dL × h)738.5667.1− 66.1\*\*\*− 59.7^†††^758.4582.6− 154.5\*\*\*− 148.1^†††^Insulin AUC~0--3h~ (µU/mL × h)119.1132.514.3\*\*8.5114.9131.814.6\*\*\*8.8C-peptide AUC~0--3h~ (ng/mL × h)12.1711.70− 0.52\*0.3912.5212.18− 0.060.85^††^PYY AUC~0--3h~ (pg/mL × h)490.4466.0− 38.0\*\*\*53.4^†††^543.8352.1− 167.5\*\*\*− 76.1^†††^Active GLP-1 AUC~0--3h~ (pmol/L × h)14.616.31.5\*0.316.033.217.2\*\*\*16.0^†††^Total GLP-1 AUC~0--3h~ (pmol/L × h)31.842.59.53\*\*\*2.9230.235.24.30\*− 2.31Glucagon AUC~0--3h~ (pg/mL × h)415.4450.136.0\*\*\*9.4403.2408.70.5− 26.1^†^GIP AUC~0--3h~ (pg/mL × h)1225.41638.6408.9\*\*\*474.4^†††^1164.3919.9− 275.5\*\*\*− 210.0^††^\**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 vs baseline; ^†^*p* \< 0.05, ^††^*p* \< 0.01, and ^†††^*p* \< 0.001 vs placebo*LSM* least squares mean, *HbA1c* hemoglobin A1c, *AUC* area under the curve, *PYY* peptide YY, *GLP-1* glucagon-like peptide-1, *GIP* glucose-dependent insulinotropic polypeptide

Compared with placebo, DS-8500a 50 mg and 75 mg had significant lowering effects on FPG \[− 12.7 mg/dL (*p* = 0.0004) and − 14.4 mg/dL (*p* \< 0.0001)\] (Fig. [4](#Fig4){ref-type="fig"}), as well as glucose AUC~0--3h~ \[− 50.6 mg/dL × h (*p* = 0.002) and − 59.7 mg/dL × h (*p* = 0.0003)\], and 2hr-PPG \[− 18.5 mg/dL (*p* = 0.0102) and − 22.0 mg/dL (*p* = 0.0022), respectively\]. DS-8500a at any dose did not lower any of these parameters to a greater extent than sitagliptin (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Change in fasting plasma glucose (FPG) from baseline to Week 12. \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs placebo

DS-8500a also affected lipid parameters. Compared with placebo, both DS-8500a at 50 and 75 mg significantly reduced total cholesterol \[− 7.0% (*p* \< 0.0001), − 6.2% (*p* = 0.0002), respectively vs placebo\], LDL-cholesterol \[− 7.3% (*p* = 0.0044), − 8.1% (*p* = 0.0014), respectively\], and TGs \[− 32.7% (*p* \< 0.0001), − 30.9% (*p* \< 0.0001), respectively\], and significantly increased HDL-cholesterol \[5.9%, (*p* = 0.0032), 6.6%, (*p* = 0.0009), respectively\] (Fig. [5](#Fig5){ref-type="fig"}). Furthermore, DS-8500a at 50 and 75 mg induced similar significant improvements in all lipid parameters compared with sitagliptin.Fig. 5Change in lipid parameters from baseline to week 12 (full analysis set). TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs placebo (ANCOVA)

The changes in AUC~0--3h~ from baseline in insulin, C-peptide, total GLP-1, active GLP-1, PYY, GIP, and glucagon at week 12 are shown in Table [2](#Tab2){ref-type="table"}. In the DS-8500a groups, AUC~0--3h~ for insulin and C-peptide was slightly increased compared with placebo from baseline to week 12. For PYY and GIP, there was a statistically significant increase in DS-8500a groups compared with placebo. However, for total GLP-1, active GLP-1, and glucagon, no significant difference was observed between the placebo and the DS-8500a groups.

Safety {#Sec11}
------

The incidence of AEs, including serious AEs, severe AEs, and treatment-emergent AEs (TEAEs) is presented in Table [3](#Tab3){ref-type="table"}. Although no serious or severe TEAEs were considered to be related to the study drugs in any of the treatment arms, three serious TEAEs occurred: two in the DS-8500a 25-mg arm and one in the DS-8500a 50-mg arm. One patient in the DS-8500a 25-mg arm was a 62-year-old man with dyslipidemia who presented with myocardial infarction 2 days after initiating treatment. He discontinued treatment and underwent emergency coronary angiography and subsequently recovered. This serious AE was considered moderate in severity and unrelated to the study drug. The second TEAE in the DS-8500a 25-mg arm involved a 43-year old man who accidentally fell and fractured his wrist approximately 2 months after initiating treatment. He underwent surgery for a suspected comminuted wrist fracture several days later. As an additional hypoglycemic drug was necessary to control his blood glucose preoperatively, he had to discontinue the study treatment. He subsequently recovered from this moderately serious AE, which was not considered related to the study drug. The patient in the DS-8500a 50-mg arm was a 50-year-old man who fell after accidentally stumbling on a step, and suffered a right orbital floor/orbital wall fracture roughly 3 months after initiating study drug treatment. This event resolved without changes in the dose of the study drug, and it was not considered related to the study drug. The two serious AEs described above in the DS-8500a 25-mg arm (myocardial infarction and wrist fracture) led to withdrawal from the study. Additionally, one event in the DS-8500a 75-mg arm led to withdrawal from the study: a 54-year-old male patient with dyslipidemia, liver function disorder, and dental caries presented with decreased hemoglobin approximately 1 month after initiating DS-8500a 75 mg. This event was considered unrelated to the study drug and was attributed to decreased dietary intake after the patient suffered an influenza infection. DS-8500a was well tolerated at all doses.Table 3Adverse eventsPlacebo (*N* = 73)DS-8500a 25 mg (*N* = 73)DS-8500a 50 mg (*N* = 74)DS-8500a 75 mg (*N* = 73)Sitagliptin 50 mg (*N* = 75)TEAE21 (28.8)27 (37.0)24 (32.4)22 (30.1)27 (36.0)  Drug-related TEAE2 (2.7)2 (2.7)4 (5.4)2 (2.7)5 (6.7)Serious TEAE2 (2.7)2 (2.7)1 (1.4)0 (0.0)0 (0.0)  Serious drug-related TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Severe TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)  Severe drug-related TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Clinically relevant hypoglycemia0 (0.0)0 (0.0)2 (2.7)0 (0.0)0 (0.0)  Clinically relevant drug-related hypoglycemia0 (0.0)0 (0.0)2 (2.7)0 (0.0)0 (0.0)Clinically relevant cardiovascular events0 (0.0)1 (1.4)0 (0.0)0 (0.0)0 (0.0)  Clinically relevant drug-related cardiovascular events0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)TEAE leading to dose withdrawal0 (0.0)2 (2.7)0 (0.0)1 (1.4)1 (1.3)*TEAE* treatment-emergent adverse event

There were two cases of clinically relevant drug-related hypoglycemia reported in the DS-8500a 50-mg group. These patients were asymptomatic (blood glucose level ≤ 70 mg/dL without showing any typical hypoglycemic symptoms). One of the patients was a 69-year-old man who presented with two episodes of asymptomatic hypoglycemia (glucose = 60 mg/dL) 1 month after initiating study treatment. Both episodes resolved without treatment or any changes in the study drug dose. The other patient was a 74-year-old woman who presented with asymptomatic hypoglycemia the day after beginning treatment. Her glucose level was 60 mg/dL, and she recovered without treatment or any changes in the study drug dose.

Discussion {#Sec12}
==========

This was a phase 2b study conducted in Japan to evaluate the efficacy and safety of DS-8500a (25-, 50-, 75-mg doses), a novel GPR119 agonist, in patients with T2DM. The results demonstrated that compared with placebo, DS-8500a at once-daily doses of 25, 50, or 75 mg showed dose-dependent decreases in HbA1c levels from baseline to week 12. DS-8500a 50 and 75 mg also demonstrated significant lowering effects on FPG, glucose AUC~0--3h~, and 2hr-PPG compared with placebo. All doses of DS-8500a were well tolerated, and there were no serious drug-related TEAEs reported in any treatment group.

The glucose-lowering effects of other GPR119 agonists are typically abrogated after 2--4 weeks of treatment \[[@CR16], [@CR17]\]. However, in the present study, the decreases in FPG, 2hr-PPG, glucose AUC~0--3h~, and HbA1c by DS-8500a were maintained over time up to 12 weeks. This result can be partially explained by structural differences between the different GPR119 molecules. Other GPR119 agonists contain a piperidine ring and have both agonistic and antagonistic activities \[[@CR18]\]. In contrast, DS-8500a, which does not contain a piperidine ring, has full agonist activity. Additionally, racial differences have been observed when comparing T2DM pathology between Asians and Caucasians \[[@CR19], [@CR20]\], with insulin secretagogues showing greater efficacy in Asians \[[@CR21], [@CR22]\].

In a hyperglycemic clamp study, patients treated with DS-8500a 75 mg for 4 weeks exhibited increases in first- and second-phase insulin secretion: AUC (*p* = 0.0011, *p* = 0.0112), as well as first/second-phase C-peptide secretion: AUC (*p* = 0.0012, *p* \< 0.0001) compared with placebo \[[@CR23]\]. From these results, we hypothesized that the decrease in 2hr-PPG after breakfast may have been due to increased insulin secretion, which was observed in the clamp study. However, in this study we did not observe an increase in insulin secretion vs placebo with either DS-8500a or sitagliptin treatment.

In this study, sitagliptin was chosen as a comparator because sitagliptin is moderately effective, highly safe, and is the most widely used dipeptidyl peptidase-4 (DPP-4) inhibitor in Japan. In our study, DS-8500a (at any dose) did not lower any of the glucose-related parameters to a greater extent than sitagliptin. However, DS-8500a treatment resulted in a notable improvement in the lipid profile, which has not been observed with sitagliptin or other DPP-4 inhibitors. Furthermore, DPP-4 inhibitors do not influence cardiovascular outcomes, but DS-8500a is expected to have a positive effect in this regard. On the basis of these potential effects of DS-8500a, we consider that this drug may have important clinical significance for treatment of T2DM.

Compared with sitagliptin, DS-8500a showed a weaker effect on glucose AUC after a single dose, but greater efficacy on HbA1c levels after multiple doses in a non-clinical pharmacology study \[[@CR24]\]. However, DS-8500a did not show greater efficacy on HbA1c than sitagliptin in our 12-week clinical study. There are several possible reasons for this discrepancy between the clinical and non-clinical results. (1) Both DS-8500a and sitagliptin increased GLP-1 secretion in non-clinical studies; however, on the basis of least squares mean (LSM) vs placebo results, DS-8500a did not show such efficacy in our clinical trial, although a significant difference was observed for sitagliptin. This suggests that DS-8500a may have a weaker blood glucose-lowering effect than sitagliptin. (2) Sitagliptin suppressed glucagon secretion in the present study, but DS-8500a did not. Because glucagon raises plasma glucose levels by promoting glucose production in the liver, it is possible that the influence on glucagon may have accounted for the difference in blood glucose-lowering effects of sitagliptin vs DS-8500a. (3) GIP levels significantly increased in the DS-8500a group compared with the placebo and sitagliptin groups in the present study (Table [2](#Tab2){ref-type="table"}). In a non-clinical study, DS-8500a also increased GIP levels compared with vehicle (unpublished data). GIP has been suggested to be involved in insulin secretion and to contribute to plasma glucose reduction by facilitating the cellular uptake of glucose in peripheral tissues \[[@CR25]\]. Although GIP modulation by DS-8500a is unknown, it is possible that such an effect might have influenced the difference in blood glucose lowering with sitagliptin. (4) PYY has been reported to be degraded by DPP-4 \[[@CR26]\]. Our present findings showed a significant increase in the PYY levels in the DS-8500a 75-mg group compared with the placebo and sitagliptin groups. PYY has an appetite-suppressing effect; however, because no AEs related to appetite suppression were reported, the extent of the contribution of this effect is unknown. Nevertheless, it is possible that PYY levels might have influenced the difference in plasma glucose-lowering effects of sitagliptin.

Regarding the effect of DS-8500a on lipid profile, the present study showed that treatment with DS-8500a significantly improved total cholesterol, LDL-cholesterol, and TG levels. Improvements in lipid profiles have also been reported for other GPR119 agonists, including GSK1292263 \[[@CR27]\] and PSN821 \[[@CR28]\]. In the present study, the changes in HbA1c and lipids were not correlated, which suggests that they might be mediated via different mechanisms of action. The mechanism of action of the abovementioned changes in lipids is unknown. Preliminary data suggest that GPR119 agonists slow the systemic appearance of cholesterol after an oral cholesterol load in rats, or that they might promote the clearance of chylomicrons or other TG-rich lipoproteins from circulation \[[@CR29]\]. The current hypothesis is that the mechanism of the TG-lowering effect by DS-8500a may be related to lipoprotein lipase activation by GIP. GIP, but not GLP-1, can activate lipoprotein lipase through phosphoinositide 3-kinase \[[@CR30]\], and GIP has been shown to reduce plasma TGs in dogs \[[@CR31]\]. Additional studies are clearly needed to evaluate the mechanism of action of GPR119 agonists on lipids.

When placing the present findings in the context of the current treatment regimen for T2DM in Japan, DS-8500a is expected to protect β-cells by enhancing first-phase insulin secretion. We believe this therapy will be effective for patients in stages of diabetes in which β-cells are not yet exhausted.

Limitations {#Sec13}
-----------

The length of the present study (12 weeks of treatment with DS-8500a) may limit the significance of the results, as this is insufficient to show the long-term efficacy of DS-8500a. It will be necessary to confirm not only the long-term efficacy of DS-8500a but also the efficacy in patients in advanced stages of diabetes. Additionally, as this study was conducted in Japan, our results cannot be extrapolated to other patient populations.

Conclusions {#Sec14}
===========

In summary, DS-8500a was well tolerated, and all doses significantly lowered HbA1c compared with placebo. In addition, DS-8500a at 50 and 75 mg significantly lowered FPG and 2hr-PPG compared with placebo and improved lipid parameters compared with both placebo and sitagliptin.
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